Tempest Therapeutics (NASDAQ:TPST) Rating Reiterated by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Tempest Therapeutics (NASDAQ:TPST) in a research report released on Thursday morning, Benzinga reports. The brokerage currently has a $47.00 price target on the stock.

Other equities research analysts have also issued reports about the stock. Scotiabank started coverage on shares of Tempest Therapeutics in a report on Thursday, March 14th. They set a sector outperform rating and a $13.00 price target for the company. William Blair reiterated an outperform rating on shares of Tempest Therapeutics in a research note on Wednesday, March 20th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of Buy and a consensus price target of $20.75.

Tempest Therapeutics Price Performance

Tempest Therapeutics stock opened at $2.03 on Thursday. Tempest Therapeutics has a 52-week low of $0.17 and a 52-week high of $9.77. The firm has a fifty day moving average of $3.24 and a 200-day moving average of $3.69. The firm has a market capitalization of $45.11 million, a P/E ratio of -1.18 and a beta of -1.78. The company has a quick ratio of 3.13, a current ratio of 3.13 and a debt-to-equity ratio of 0.20.

Tempest Therapeutics (NASDAQ:TPST) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.08. As a group, analysts predict that Tempest Therapeutics will post -1.58 EPS for the current year.

Institutional Trading of Tempest Therapeutics

An institutional investor recently bought a new position in Tempest Therapeutics stock. MayTech Global Investments LLC bought a new stake in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 10,000 shares of the company’s stock, valued at approximately $44,000. Tempest Therapeutics accounts for approximately 0.0% of MayTech Global Investments LLC’s holdings, making the stock its 29th largest position. MayTech Global Investments LLC owned approximately 0.05% of Tempest Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 22.52% of the company’s stock.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.